The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, double-dummy, and positive control clinic
trial which explores the efficacy and safety of ornithine aspartate granules in the treatment
of non-alcoholic fatty liver disease against silymarin capsules. The hypothesis is that the
ornithine aspartate granules have similar or better efficacy than the silymarin capsules.
Phase:
Phase 4
Details
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Collaborators:
Beijing Ditan Hospital Beijing YouAn Hospital First Affiliated Hospital, Sun Yat-Sen University Wuhan Union Hospital, China